Cyclophosphamide in the treatment of idiopathic pulmonary fibrosis: A prospective study in patients who failed to respond to corticosteroids

Chest

Volumn 117, Issue 6, 2000, Pages 1619-1626

  Zisman, David A ^a   Lynch III, Joseph P ^a   Toews, Galen B ^a   Kazerooni, Ella A ^a   Flint, Andrew ^a   Martinez, Fernando J ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Corticosteroids; Cyclophosphamide; Pulmonary fibrosis; Therapy; Treatment

Indexed keywords

CARBON MONOXIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPIGMENTATION; LUNG BIOPSY; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; PRIORITY JOURNAL; PULSE OXIMETRY; RASH; THORAX RADIOGRAPHY; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

EID: 0034047115     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.6.1619     Document Type: Article

References (41)

1. 1 Agusti G, Xaubet Z, Roca J, et al. Interstitial pulmonary fibrosis with and without associated collagen vascular disease: results of a two year follow up. Thorax 1992; 47:1035-1040
2. 2 Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med 1998; 157:1063-1072
3. 3 Schwartz DA, Helmers RA, Calvin JR, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:450-454
4. 4 Schwartz D, vanFossen D, Davis C, et al. Determinants of progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1994; 149:444-449
5. 5 Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis: past, present, and future. Chest 1996; 110:1058-1067
6. 6 Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124:1-8
7. 7 Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: response to corticosteroid therapy and its effect on survival. Thorax 1980; 35:593-599
8. 8 Johnson MA, Kwan S, Snell NJC, et al. Randomized controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 1989; 44:280-288
9. 9 Raghu G, DePaso WJ, Cain K, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144:291-296
10. 10 King TE Jr. Idiopathic pulmonary fibrosis. In: Schwarz M, King T Jr., eds. Interstitial lung disease. Hamilton, OR: B.C. Decker; 1998;597-644
11. 11 Reynolds HY. Diagnostic and management strategies for diffuse interstitial lung disease. Chest 1998; 113:192-202
12. 12 van Oortegem K, Wallaert B, Marquette CH, et al. Determinants of response to immunosuppressive therapy in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7:1950-1957
13. 13 Meier-Sydow J, Weiss SM, Buhl R, et al. Idiopathic pulmonary fibrosis: current clinical concepts and challenges in management. Semin Respir Crit Care Med 1994; 15:77-96
14. 14 Brown C, Turner-Warwick M. The treatment of cryptogenic fibrosing alveolitis with immunosuppressant drugs. Q J Med 1971; 158:289-302
15. 15 Turner-Warwick M, Haslam P. The value of serial bronchoalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveolitis. Am Rev Respir Dis 1987; 135:26-34
16. 16 Weese W, Levine B, Kazemi H. Interstitial lung disease resistant to corticosteroid therapy: report of three cases treated with azathioprine or cyclophosphamide. Chest 1975; 67:57-60
17. 17 Meuret G, Fueter R, Gloor F. Early stage of fulminant idiopathic pulmonary fibrosis cured by intense combination therapy using cyclophosphamide, vincristine, and prednisone. Respiration 1978; 36:228-233
18. 18 Flusser G, Gurman G, Zirkin H, et al. Desquamative interstitial pneumonitis causing acute respiratory failure, responsive only to immunosuppressants. Respiration 1991; 58:324-326
19. 19 O'Donnell K, Keogh B, Cantin A, et al. Pharmacologic suppression of the neutrophil component of the alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1987; 136:288-293
20. 20 Baughman R, Lower E. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis. Chest 1992; 102:1090-1094
21. 21 Dayton C, Schwartz D, Helmers R, et al. Outcome of subjects with idiopathic pulmonary fibrosis who fail corticosteroid therapy: implications for further studies. Chest 1993; 103: 69-73
22. 22 Kolb M, Kirschner J, Riedel W, et al. Cyclophosphamide pulse therapy in idiopathic pulmonary fibrosis. Eur Respir J 1998; 12:1409-1414
23. 23 Johnston IDA, Prescott BJ, Chalmers JC, et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax 1997; 52:38-44
24. 24 Haslam P, Turton C, Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35:328-329
25. 25 Morris J, Koski A, Johnson L. Spirometric standards for healthy non-smoking adults. Am Rev Respir Dis 1971; 103: 57-67
26. 26 Goldman H, Becklake M. Respiratory function tests: normal values at median altitudes and the prediction of normal results. Am Rev Tuberc 1959; 79:457-467
27. 27 Crapo R, Morris A. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981; 123:185-189
28. 28 Watters LC, King TE, Schwarz MI, et al. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1986; 133:97-103
29. 29 Kazerooni EA, Martinez FJ, Flint A, et al. Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am J Roentgenol 1997; 169: 977-983
30. 30 Eliasson O, Cole S, Degraff A. Adverse effects of cyclophosphamide in idiopathic pulmonary fibrosis. Conn Med 1985; 49:286-289
31. 31 Hanson D, Winterbauer RH, Kirtland SH, et al. Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. Chest 1995; 108:305-310
32. 32 Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis: are they helpful for predicting outcome? Chest 1997; 111:51-57
33. 33 Flint A, Martinez FJ, Young ML, et al. Influence of sample number and biopsy site on the histologic diagnosis of diffuse lung disease. Ann Thorac Surg 1995; 60:1605-1608
34. 34 Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest 1998; 113:396-400
35. 35 Terriff B, Kwan S, Chan-Yeung M, et al. Fibrosing alveolitis: chest radiography and CT as predictors of clinical and functional impairment at follow-up in 26 patients. Radiology 1992; 184:445-449
36. 36 Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488-498
37. 37 Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996; 124:477-484
38. 38 Lynch J III, McCune J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med 1997; 155:395-420
39. 39 Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40:2187-2198
40. 40 Radis CD, Kahl LE, Baker GL, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis: a 20 year follow-up study. Arthritis Rheum 1995; 38:1120-1127
41. 41 Winterbauer RH, Hammar SP, Hallman KO, et al. Diffuse interstitial pneumonitis: clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med 1978; 65:661-672